Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment

•The cycle threshold (Ct) value of RT-PCR was not significantly reduced by remdesivir.•Infectious virus was not detected after the third dose of remdesivir despite dexamethasone treatment.•SARS-CoV-2 shedding significantly decreased after remdesivir treatment, regardless of the Ct value.•Rapid antig...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infection 2022-06, Vol.84 (6), p.834-872
Main Authors: Yoon, Jin Gu, Yoo, Jin Sae, Lee, Jungmin, Hyun, Hak-Jun, Seong, Hye, Noh, Ji Yun, Cheong, Hee Jin, Kim, Woo Joo, Kim, Young Rong, Heo, Jung Yeon, Bae, Joon-Yong, Cui, Chunguang, Lee, Sohyun, Park, Man-Seong, Song, Joon Young
Format: Article
Language:English
Subjects:
Adenosine Monophosphate - analogs & derivatives
Alanine - analogs & derivatives
Antiviral Agents - therapeutic use
COVID-19 Drug Treatment
Dexamethasone - therapeutic use
Humans
Letter to the Editor
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•The cycle threshold (Ct) value of RT-PCR was not significantly reduced by remdesivir.•Infectious virus was not detected after the third dose of remdesivir despite dexamethasone treatment.•SARS-CoV-2 shedding significantly decreased after remdesivir treatment, regardless of the Ct value.•Rapid antigen test is a viable adjunctive tool that guides the decision to terminate the isolation.
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2022.03.022